Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. Neuroendocrine tumors are three types which include Pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma. Neuroendocrine cells also present in the neuroendocrine system that includes pituitary gland, pineal gland, thyroid gland, parathyroid and adrenal glands. Physiological changes in the neuroendocrine cells may cause formation of two types of tumors–functional and nonfunctional tumors. Functional tumors develop another endocrine cells and nonfunctional tumors may cause physiological changes and based on the cause it treated. Neuroendocrine carcinoma are classified in two categories namely carcinoids and pancreatic endocrine tumors.
Carcinoid tumors, originating in the neuroendocrine system, usually appear in the digestive system i.e. in stomach and appendix. Besides, some carcinoid tumors develop in other organs such as lungs, thymus and ovaries. Due to their gradual growth, the symptoms of neuroendocrine carcinoma are not visible at early stages and are discovered only during undergoing an unrelated surgery. Tumors originating in the pancreas are named depending on the type of hormone released. For example, a tumor called gastrinoma is a tumor that release gastrin which results in excessive secretion of gastric acid.
Surgery is the first line therapy for removing affected neuroendocrine cells, thereafter, medication is used for treating neuroendocrine carcinoma. Sunitinib and Afinitor drugs are commonly used drugs for treatment of neuroendocrine carcinoma treatment.
Immune system suppression and exposure to arsenic are the major risk factors for neuroendocrine carcinoma.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1278
Neuroendocrine Carcinoma Market: Drivers and Restraints
Significant increase in funding for treatment of cancer by various international organizations such as American Cancer Academy and world Health Organization is expected to boost overall neuroendocrine carcinoma treatment market. Furthermore, significant increase in healthcare spending along with high prevalence rate of neuroendocrine carcinoma in developing region is expected to boost overall neuroendocrine carcinoma market. Though market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restrains for neuroendocrine carcinoma market.
Neuroendocrine Carcinoma Market: Segmentation
Neuroendocrine Carcinoma market further segmented into followingtype.
- Platinum derivatives
- Topoisomerase inhibitor
- Anthracycline antibiotic
By End User
- Drug store
Neuroendocrine Carcinoma Market: Overview
Neuroendocrine tumors (NETs) are malignant tumors that originate in endocrine cells and targets digestive tract that misbalances hormonal release. The market is expected to witness healthy CAGR during the forecast period.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1278
Neuroendocrine Carcinoma Market: Region- wise Outlook
The global Neuroendocrine Carcinoma Market is expected to register a impressive CAGR over the forecast period. Depending on geographic regions, global neuroendocrine carcinoma market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa
North America dominates the global neuroendocrine carcinoma market owing to presence of modern healthcare amenities along with significant healthcare expenditure in these regions. Europe occupies second place in this market with its new regulations in the major economies. Asia also shows a healthy growth rate in this market.
Neuroendocrine Carcinoma Market: Key Players
Some of the key players in this market include
- Novartis AG
- F. Hoffman La Roche
- Callisto Pharmaceuticals
- Eli Lilly & Company
- Molecular Insight Pharmaceuticals
- Amgen Inc.